Selective inhibition of plasma membrane calcium ATPase 4 improves angiogenesis and vascular reperfusion
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Authors
Kurusamy, SathishkumarLópez-Maderuelo, Dolores
Little, Robert
Cadagan, David
Savage, Aaron M
Ihugba, Jude C
Baggott, Rhiannon Rebecca
Rowther, Farjana B
Martínez-Martínez, Sara
Gómez-del Arco, Pablo
Murcott, Clare
Wang, Weiguang
Nistal, J Francisco
Oceandy, Delvac
Neyses, Ludwig
Wilkinson, Robert N
Cartwright, Elizabeth J.
Miguel Redondo, Juan
Armesilla, Angel
Issue Date
2017-07-03
Metadata
Show full item recordAbstract
Aims Ischaemic cardiovascular disease is a major cause of morbidity and mortality worldwide. Despite promising results from pre-clinical animal models, VEGF-based strategies for therapeutic angiogenesis have yet to achieve successful reperfusion of ischaemic tissues in patients. Failure to restore efficient VEGF activity in the ischaemic organ remains a major problem in current pro-angiogenic therapeutic approaches. Plasma membrane calcium ATPase 4 (PMCA4) negatively regulates VEGF-activated angiogenesis via inhibition of the calcineurin/NFAT signalling pathway. PMCA4 activity is inhibited by the small molecule aurintricarboxylic acid (ATA). We hypothesize that inhibition of PMCA4 with ATA might enhance VEGF-induced angiogenesis. Methods and results We show that inhibition of PMCA4 with ATA in endothelial cells triggers a marked increase in VEGF-activated calcineurin/NFAT signalling that translates into a strong increase in endothelial cell motility and blood vessel formation. ATA enhances VEGF-induced calcineurin signalling by disrupting the interaction between PMCA4 and calcineurin at the endothelial-cell membrane. ATA concentrations at the nanomolar range, that efficiently inhibit PMCA4, had no deleterious effect on endothelial-cell viability or zebrafish embryonic development. However, high ATA concentrations at the micromolar level impaired endothelial cell viability and tubular morphogenesis, and were associated with toxicity in zebrafish embryos. In mice undergoing experimentally-induced hindlimb ischaemia, ATA treatment significantly increased the reperfusion of post-ischaemic limbs. Conclusions Our study provides evidence for the therapeutic potential of targeting PMCA4 to improve VEGF-based pro-angiogenic interventions. This goal will require the development of refined, highly selective versions of ATA, or the identification of novel PMCA4 inhibitors.Citation
Kurusamy, S., López-Maderuelo, D., Little, R., Cadagan, D., Savage, AM., Ihugba, JC., Baggott, RR., Rowther, FB., Martínez-Martínez, S., Arco, PGD., Murcott, C., Wang, W., Francisco Nistal, J., Oceandy, D., Neyses, L., Wilkinson, RN., Cartwright, EJ., Redondo, JM., & Armesilla, AL. (2017) 'Selective inhibition of plasma membrane calcium ATPase 4 improves angiogenesis and vascular reperfusion', Journal of molecular and cellular cardiology, 109, pp. 38-47 doi: 10.1016/j.yjmcc.2017.07.001Publisher
ElsevierJournal
Journal of Molecular and Cellular CardiologyAdditional Links
http://www.sciencedirect.com/science/article/pii/S0022282817301281Type
Journal articleLanguage
enISSN
0022-2828ae974a485f413a2113503eed53cd6c53
10.1016/j.yjmcc.2017.07.001
Scopus Count
Collections
Except where otherwise noted, this item's license is described as https://creativecommons.org/CC BY-NC-ND 4.0